Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials-Reference-Cited by-同舟云学术

Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

Published:2020-07-25 Issue: Volume: Page:
ISSN:2578-5745
Container-title:ACR Open Rheumatology
language:en
Short-container-title:ACR Open Rheuma

Author:

Mease Philip J.¹,Gladman Dafna D.²,Gomez‐Reino Juan J.³,Hall Stephen⁴,Kavanaugh Arthur⁵,Lespessailles Eric⁶,Schett Georg⁷^ORCID,Paris Maria⁸,Delev Nikolay⁹,Teng Lichen⁸,Wollenhaupt Jürgen¹⁰

Affiliation:

1. Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington and University of Washington School of Medicine Seattle

2. Krembil Research Institute Toronto Western Hospital Toronto Ontario Canada

3. Fundación Dominguez, Hospital Clínico Universitario Santiago Spain

4. Monash University, Cabrini Health Melbourne Australia

5. University of California San Diego School of Medicine La Jolla

6. Regional HospitalUniversity of Orléans Orléans France

7. Friedrich‐Alexander‐Universität Erlangen‐Nürnberg, Erlangen, Germany und Universitätsklinikum Erlangen Erlangen Germany

8. Amgen Inc Thousand Oaks California

9. Celgene Corporation Summit New Jersey

10. Jürgen Wollenhaupt: Schön Klinik Hamburg Eilbek Hamburg Germany

Funder

Celgene

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11156

Reference34 articles.

1. Psoriatic arthritis;Ritchlin CT;N Engl J Med,2017

2. Psoriatic arthritis: epidemiology, clinical features, course, and outcome;Gladman D;Ann Rheum Dis,2005

3. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: treatment recommendations for psoriatic arthritis 2015;Coates LC;Arthritis Rheumatol,2016

4. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey;Lebwohl MG;Am J Clin Dermatol,2016

5. Physician perspectives in the managment of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey;Van de Kerkhof PC;J Eur Acad Dermatol Venereol,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuberculosis reactivation following apremilast therapy for psoriasis: Time to consider routine TB screening?;Australasian Journal of Dermatology;2024-09-11

2. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies;Expert Review of Clinical Immunology;2024-07-29

3. A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a “Safety Checklist”;Drug Safety;2024-07-16

4. Clinical practice guideline for the treatment of psoriatic arthritis in Colombia;Revista Colombiana de Reumatología (English Edition);2023-07

5. Clinical practice guideline for the treatment of psoriatic arthritis in Colombia;Revista Colombiana de Reumatología;2023-07